JP2014500258A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500258A5
JP2014500258A5 JP2013539955A JP2013539955A JP2014500258A5 JP 2014500258 A5 JP2014500258 A5 JP 2014500258A5 JP 2013539955 A JP2013539955 A JP 2013539955A JP 2013539955 A JP2013539955 A JP 2013539955A JP 2014500258 A5 JP2014500258 A5 JP 2014500258A5
Authority
JP
Japan
Prior art keywords
formulation
oral
transmucosal
mucosa
retinide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500258A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/060838 external-priority patent/WO2012068147A1/en
Publication of JP2014500258A publication Critical patent/JP2014500258A/ja
Publication of JP2014500258A5 publication Critical patent/JP2014500258A5/ja
Pending legal-status Critical Current

Links

JP2013539955A 2010-11-15 2011-11-15 制御放出粘膜付着システム Pending JP2014500258A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41398210P 2010-11-15 2010-11-15
US61/413,982 2010-11-15
PCT/US2011/060838 WO2012068147A1 (en) 2010-11-15 2011-11-15 Controlled release mucoadhesive systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016215838A Division JP6415518B2 (ja) 2010-11-15 2016-11-04 制御放出粘膜付着システム

Publications (2)

Publication Number Publication Date
JP2014500258A JP2014500258A (ja) 2014-01-09
JP2014500258A5 true JP2014500258A5 (cg-RX-API-DMAC7.html) 2014-12-18

Family

ID=46084375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013539955A Pending JP2014500258A (ja) 2010-11-15 2011-11-15 制御放出粘膜付着システム
JP2016215838A Active JP6415518B2 (ja) 2010-11-15 2016-11-04 制御放出粘膜付着システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016215838A Active JP6415518B2 (ja) 2010-11-15 2016-11-04 制御放出粘膜付着システム

Country Status (8)

Country Link
US (2) US10758619B2 (cg-RX-API-DMAC7.html)
EP (1) EP2640368B1 (cg-RX-API-DMAC7.html)
JP (2) JP2014500258A (cg-RX-API-DMAC7.html)
CN (1) CN103313706A (cg-RX-API-DMAC7.html)
AU (2) AU2011329066B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013011942A2 (cg-RX-API-DMAC7.html)
CA (1) CA2817982C (cg-RX-API-DMAC7.html)
WO (1) WO2012068147A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
JP2015519403A (ja) * 2012-06-14 2015-07-09 エントレガ，インコーポレイテッド 活性剤送達のための粘膜付着性デバイス
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2016011535A1 (en) 2014-07-25 2016-01-28 Laurent Pharmaceuticals Solid oral formulation of fenretinide
WO2017147169A1 (en) * 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
WO2019004088A1 (ja) * 2017-06-27 2019-01-03 株式会社バイオセレンタック 粘膜付着性経口製剤
WO2021122793A1 (en) * 2019-12-17 2021-06-24 Norinvent Ab Sulfated disaccharides as enhancers of transmucosal drug uptake
EP4076381B1 (en) * 2019-12-20 2024-12-04 LTS Lohmann Therapie-Systeme AG Transmucosal therapeutic system containing agomelatine
MX2022007331A (es) * 2019-12-20 2022-07-27 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transmucosal que contiene agomelatina.

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4608337A (en) 1980-11-07 1986-08-26 The Wistar Institute Human hybridomas and the production of human monoclonal antibodies by human hybridomas
US4701409A (en) 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4693975A (en) 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
JPH0729915B2 (ja) 1986-02-01 1995-04-05 帝國製薬株式会社 シ−ト状口腔内貼付剤
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5198338A (en) 1989-05-31 1993-03-30 Temple University Molecular probing for human t-cell leukemia and lymphoma
CA2063409A1 (en) 1989-07-03 1991-01-04 Carlo M. Croce Tcl-5 gene rearrangement involved in t-cell leukemia and melanoma
US5149628A (en) 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5633135A (en) 1991-12-11 1997-05-27 Thomas Jefferson University Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
WO1993012136A1 (en) 1991-12-11 1993-06-24 Thomas Jefferson University Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region
US6040140A (en) 1991-12-11 2000-03-21 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
US5629019A (en) * 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
EP0667920B1 (en) 1992-10-29 2003-01-15 Thomas Jefferson University Methods of detecting micrometastasis of prostate cancer
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5464870A (en) 1993-02-10 1995-11-07 Ortho Pharmaceutical Corporation Methods of inhibiting development of leukoplakia with fenretinide
GB9307754D0 (en) 1993-04-15 1993-06-02 Perry Robert E Diagnostic probes and therapeutic products
WO1994026930A1 (en) 1993-05-14 1994-11-24 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
US5985598A (en) 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US7175995B1 (en) 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US5567586A (en) 1995-05-18 1996-10-22 Thomas Jefferson University Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US5928884A (en) 1996-02-09 1999-07-27 Croce; Carlo M. FHIT proteins and nucleic acids and methods based thereon
AU4003597A (en) 1996-09-04 1998-03-26 Howard Florey Institute Of Experimental Physiology And Medicine Methods of diagnosing and treating cancer
WO1998035707A1 (en) 1997-02-18 1998-08-20 Thomas Jefferson University Compositions that bind to pancreatic cancer cells and methods of using the same
AU6951098A (en) 1997-04-04 1998-10-30 The Texas A & M University System Noninvasive detection of colonic biomarkers using fecal messenger rna
AU750809B2 (en) * 1997-09-26 2002-07-25 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
CO5080817A1 (es) 1997-10-21 2001-09-25 Cancer Res Campaign Tech Ltd Determinacion de anormalidades en el crecimiento celular
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
CA2335315A1 (en) 1998-07-20 2000-01-27 Thomas Jefferson University Nitrilase homologs
US6255293B1 (en) 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
JP2003508011A (ja) 1999-02-25 2003-03-04 トマス・ジエフアーソン・ユニバーシテイ ヒトｆｅｚ１遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
WO2000055169A1 (en) 1999-03-15 2000-09-21 Thomas Jefferson University TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU6227400A (en) 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US20040132017A1 (en) 1999-12-16 2004-07-08 Robert Richards Oxidoreductase gene associated with the fra16d fragile site
US20030206958A1 (en) 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US6891031B2 (en) 2000-02-18 2005-05-10 The Regents Of The University Of California Coordinate cytokine regulatory sequences
US20010026796A1 (en) 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
CA2406366A1 (en) 2000-04-11 2001-10-18 Thomas Jefferson University Muir-torre-like syndrome infhit deficient mice
US20020086331A1 (en) 2000-05-16 2002-07-04 Carlo Croce Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US7060811B2 (en) 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US7691404B2 (en) * 2000-11-06 2010-04-06 Samyang Corporation Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
JP4384409B2 (ja) * 2000-12-05 2009-12-16 チルドレンズ・ホスピタル・ロス・アンジエルス バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
WO2002064171A1 (en) 2001-02-12 2002-08-22 Thomas Jefferson University Adenoviral transduction of fragile histidine triad (fhit) into cancer cells
WO2002064172A2 (en) 2001-02-12 2002-08-22 Thomas Jefferson University Fhit gene therapy prevents tumor development in fhit-deficient mice
US20040033502A1 (en) 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
JP2003055201A (ja) 2001-08-13 2003-02-26 Lion Corp ビタミンａ類含有可溶化組成物及びビタミンａ類の安定化方法
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
WO2003040347A2 (en) 2001-11-09 2003-05-15 The Ohio State University Research Foundation Baalc expression as a diagnostic marker for acute leukemia
GB0128898D0 (en) 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
AU2002231843A1 (en) 2002-02-12 2003-09-04 Nokia Corporation Method for controlling data transmission, and data transmission system
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2463595A1 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of bcl2 gene expression using short interfering nucleic acid (sina)
MXPA04008722A (es) 2002-03-08 2005-07-13 Eisai Co Ltd Compuestos macrociclicos utiles como farmaceuticos.
ATE529535T1 (de) 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
EP1496928A4 (en) 2002-04-08 2005-08-10 Ciphergen Biosystems Inc SERUM BIOMARKERS IN HEPATOCELLULAR CARCINOMA
DE60329836D1 (de) 2002-04-29 2009-12-10 Univ Jefferson Humane chronische lymphozytische leukämie im mausmodell durch gezielte expression von tcl1
EP1530418A4 (en) 2002-05-31 2005-10-12 Univ Leland Stanford Junior METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS
US20040002872A1 (en) * 2002-06-28 2004-01-01 Wright Donald Joe PDA-based prescription messaging method and object-oriented system
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20050266443A1 (en) 2002-10-11 2005-12-01 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
JP2006512908A (ja) 2002-10-11 2006-04-20 トーマス ジェファーソン ユニバーシティー 腫瘍抑制遺伝子および組成物ならびにその作製法および使用法
CA2504283A1 (en) * 2002-10-31 2004-05-21 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
CA2504605C (en) 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
DE10256774A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption
US7785621B2 (en) * 2003-01-31 2010-08-31 Childrens Hospital Los Angeles Oral compositions of fenretinide having increased bioavailability and methods of using the same
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7183384B2 (en) 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
AU2003286741A1 (en) 2003-05-02 2004-11-26 Thomas Jefferson University Methods and compositions for diagnosis and therapy of parkin-associated disorders
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US8412541B2 (en) 2003-08-14 2013-04-02 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis for medical diagnosis
US20050084883A1 (en) 2003-08-25 2005-04-21 The Johns Hopkins University School Of Medicine Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis
EP1670955A2 (en) 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
JPWO2005028648A1 (ja) 2003-09-22 2007-11-15 愛知県 リンパ腫の病型および予後診断方法
US20070054849A1 (en) 2003-09-24 2007-03-08 Oncotherapy Science, Inc. Method for diagnosing hepatocellular carcinomas
US20050186589A1 (en) 2003-11-07 2005-08-25 University Of Massachusetts Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
US20050164252A1 (en) 2003-12-04 2005-07-28 Yeung Wah Hin A. Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
JP4120002B2 (ja) 2004-01-07 2008-07-16 愛知県 ｍｉＲＮＡを用いた癌の予後判定方法、癌の遺伝子治療ベクター及び癌治療用医薬組成物
US20050256072A1 (en) 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP1713938A2 (en) 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
JP4980878B2 (ja) 2004-02-23 2012-07-18 エラスムス ユニバーシティ メディカル センター ロッテルダム 遺伝子発現プロファイリングによる急性骨髄性白血病の分類、診断、および予後
EP1734944B1 (en) 2004-03-18 2012-06-13 Fondazione IRCCS Istituto Nazionale dei Tumori 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
WO2005094263A2 (en) 2004-03-23 2005-10-13 Pintex Pharmaceuticals, Inc. Methods of determining the prognosis and treatment of subjects with colon cancer
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
KR20070004957A (ko) 2004-04-20 2007-01-09 제나코 바이오메디컬 프로덕츠, 인코포레이티드 ｎｃＲＮＡ 검출 방법
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
EP1771563A2 (en) 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
US7635563B2 (en) 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
US20060037088A1 (en) 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer
KR100876771B1 (ko) 2004-08-17 2009-01-07 삼성전자주식회사 무선 통신 시스템에서 제어 정보 압축 방법과 스캐닝 정보 송수신 방법 및 장치
EP1797183B1 (en) 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
WO2008073922A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
ATE544774T1 (de) 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc Rnai-modulation von mll-af4 und verwendungen dafür
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
DE602006016739D1 (de) 2005-01-25 2010-10-21 Rosetta Inpharmatics Llc Verfahren zur quantifizierung kleiner rna-moleküle
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
WO2006086737A2 (en) 2005-02-11 2006-08-17 Wisconsin Alumni Reasearch Foundation Mir-155 assay
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
GB2425311A (en) 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
US8071559B2 (en) 2005-05-02 2011-12-06 Cold Spring Harbor Laboratory Compositions and methods for cancer diagnosis and treatment
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070065844A1 (en) 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070123482A1 (en) 2005-08-10 2007-05-31 Markus Stoffel Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP2796554A3 (en) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Compositions for use in treating BCL2-associated cancers
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
EP1940456A4 (en) 2005-10-05 2009-10-21 Univ Ohio State Res Found WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
CN103361424A (zh) 2006-01-05 2013-10-23 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2514433B1 (en) 2006-01-05 2015-10-21 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis, prognosis and treatment of lung cancer
US20090007281A1 (en) 2006-01-13 2009-01-01 Battelle Memorial Institute Animal Model for Assessing Copd-Related Diseases
CA2643037C (en) * 2006-02-27 2014-08-05 Noven Pharmaceuticals, Inc. Compositions and methods for delivery of amino-functional drugs
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
AU2007233155B2 (en) 2006-03-29 2012-04-26 Scitech Development Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
EP2007889A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
CA2650026C (en) 2006-04-24 2013-01-22 The Ohio State University Research Foundation Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice
US20100035911A1 (en) * 2006-05-17 2010-02-11 Barry James Maurer Drug combinations to treat hyperproliferative disorders
WO2008029295A2 (en) 2006-06-30 2008-03-13 Rosetta Genomics Ltd A method for detecting nucleic acids
ES2447850T3 (es) 2006-07-13 2014-03-13 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon
EA016145B1 (ru) 2006-08-30 2012-02-28 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Новые низкомолекулярные ингибиторы mdm2 и их применение
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP5426383B2 (ja) 2006-09-19 2014-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 慢性リンパ球性白血病におけるｍｉＲ−２９およびｍｉＲ−１８１によって制御されるＴＣＬ１発現
AU2007299804A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
AU2007299748A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention
JP2008086201A (ja) 2006-09-29 2008-04-17 Gifu Prefecture Kenkyu Kaihatsu Zaidan マイクロｒｎａ生成の検出方法と癌の診断・治療およびマイクロｒｎａ生成調整剤
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
JP2010510769A (ja) 2006-11-28 2010-04-08 キャピタルバイオ コーポレーション 食道癌の診断ならびに患者の生存の予後および改善のための方法および組成物
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
WO2008070082A2 (en) 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
CN101622350A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
WO2008073919A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US8765702B2 (en) 2007-02-27 2014-07-01 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
WO2008113758A1 (en) 2007-03-16 2008-09-25 Covalx Ag Direct mass spectrometric analysis of drug candidates targeting protein complexes
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
RU2009141359A (ru) 2007-04-10 2011-05-20 Нэйшнл Тайвань Юниверсити (Tw) Посттерапевтический прогноз выживания больных раком с использованием микрорнк
US20100144850A1 (en) 2007-04-30 2010-06-10 The Ohio State University Research Foundation Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis
US20090005336A1 (en) 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
AU2008261951A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
EP2613149B1 (en) 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
AU2008282318B2 (en) 2007-07-31 2014-02-27 The Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
EP2650383A1 (en) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
US20090061424A1 (en) 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations
CA2698771A1 (en) 2007-09-06 2009-03-12 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
US20090239818A1 (en) 2007-09-07 2009-09-24 Cheng Jin Q Effective treatment of ovarian cancer using triciribine and related compounds
ES2419129T3 (es) 2007-09-14 2013-08-19 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo
US20100305188A1 (en) 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
MX2010003299A (es) 2007-10-04 2010-04-14 Santaris Pharma As Oligonucleotidos muy cortos (micromirs).
CN101861401B (zh) 2007-10-11 2014-03-12 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
CN103898069A (zh) 2007-10-26 2014-07-02 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
JP5535076B2 (ja) 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド 肝臓癌を治療するための標的化ミクロｒｎａ
AU2008321253B2 (en) 2007-11-12 2014-01-16 Masaryk Memorial Cancer Institute Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US20090123933A1 (en) 2007-11-12 2009-05-14 Wake Forest University Health Sciences Microrna biomarkers in lupus
CN101918594A (zh) 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
CN101215560B (zh) 2007-12-26 2010-09-29 暨南大学 一种具有抗白血病作用的miR-21反义寡核苷酸及其应用
KR20100127768A (ko) 2008-02-01 2010-12-06 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
US20090207140A1 (en) 2008-02-19 2009-08-20 Sony Ericsson Mobile Communications Ab Identifying and responding to multiple time-overlapping touches on a touch panel
CN102015027A (zh) 2008-02-28 2011-04-13 俄亥俄州立大学研究基金会 与人慢性淋巴细胞性白血病(ccl)相关的微rna特征和其用途
AU2009219197B2 (en) 2008-02-28 2014-04-10 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dep. Of Health And Human Services MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
CA2717030A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
JP5662166B2 (ja) 2008-02-28 2015-01-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 胃癌の診断、予後診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物
US20090220589A1 (en) 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
WO2009111643A2 (en) 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
US20090253780A1 (en) 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2009131887A2 (en) 2008-04-24 2009-10-29 Merck & Co., Inc. Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
US20110107440A1 (en) 2008-06-04 2011-05-05 Andor Pivarcsi Skin cancer associated micrornas
US8900627B2 (en) 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
CN101623277B (zh) 2008-07-08 2014-07-16 上海交通大学医学院附属瑞金医院 芬维a胺及其活性衍生物的新用途及其药物组合物
US8088822B2 (en) 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
US20100021734A1 (en) 2008-07-22 2010-01-28 Covalent Materials Corporation Ceramic particles and producing method thereof
KR101031305B1 (ko) 2008-07-23 2011-04-29 국립암센터 마이크로ｒｎａ-21 저해제를 포함하는 방사선 민감성증진용 조성물
JP2012500389A (ja) 2008-08-12 2012-01-05 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法
WO2010056737A2 (en) 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010059779A1 (en) 2008-11-21 2010-05-27 The Ohio State University Research Foundation Tcl1 AS A TRANSCRIPTIONAL REGULATOR
WO2010065156A1 (en) 2008-12-05 2010-06-10 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer
AU2010218147A1 (en) 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
US20110136124A1 (en) 2009-09-23 2011-06-09 Wilson Roa Microrna expression profiles associated with lung cancer
EP2521541A2 (en) 2009-10-28 2012-11-14 ReVision Therapeutics, Inc. Prophylaxis of skin cancer with retinamides
WO2011057304A2 (en) 2009-11-09 2011-05-12 Yale University Microrna signatures differentiating uterine and ovarian papillary serous tumors
CA2812929C (en) 2009-11-12 2015-02-03 Texas Tech University Compositions and methods for treating hyperproliferative disorders
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011119553A1 (en) 2010-03-26 2011-09-29 The Ohio State University Materials and methods related to modulation of mismatch repair and genomic stability by mir-155
US20130139273A1 (en) 2010-06-24 2013-05-30 The Ohio State University Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression
US20130150430A1 (en) 2010-08-04 2013-06-13 The Ohio State University Methods for Impairing the P53/HDM2 Auto-Regulatory Loop in Multiple Myeloma Development Using mIR-192, mIR-194 and mIR-215
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2012097047A1 (en) 2011-01-11 2012-07-19 The Ohio State University Research Foundation Methods to identify chronic lymphocytic leukemia disease progression
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER

Similar Documents

Publication Publication Date Title
JP2014500258A5 (cg-RX-API-DMAC7.html)
CN101404990B (zh) 含有味道被掩蔽的活性剂的固体剂型
Hearnden et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease
Dixit et al. Oral strip technology: Overview and future potential
ES2737976T3 (es) Forma farmacéutica para administración oral como tira u oblea comestible que contiene resina de intercambio iónico para enmascarar el sabor
AU725283B2 (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
JP2009102342A5 (cg-RX-API-DMAC7.html)
JP2013501717A5 (cg-RX-API-DMAC7.html)
CN102933199A (zh) 含有烟碱的药物组合物
JP5259880B2 (ja) 経口剤
JP2013501718A5 (cg-RX-API-DMAC7.html)
CN1826117A (zh) 口腔溶解薄膜
JP2010502612A5 (cg-RX-API-DMAC7.html)
RS61753B1 (sr) Farmaceutske kompozicije koje sadrže lokalni anestetik kao što je bupivakain za lokalno administriranje u usta ili grlo
JP2002537070A (ja) 生体接着性抗菌性創傷治癒用組成物
EP3641759B1 (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
JP2015500285A5 (cg-RX-API-DMAC7.html)
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
JP5624472B2 (ja) ロペラミド塩酸塩含有フィルム製剤
KR100885178B1 (ko) 점착성 약제 조성물
CN101278948A (zh) 一种生物型药膜及其制备方法
Chauhan et al. A comprehensive review on mucoadhesive drug delivery
KR102889909B1 (ko) 연성 항콜린성 에스테르를 위한 방법 및 조성물
JP2010138124A (ja) 口腔内粘膜貼付製剤
JP2006070027A (ja) 口腔粘膜投与剤